Oncotarget

Research Papers:

Oncogenic features of the bone morphogenic protein 7 (BMP7) in pheochromocytoma

Ines Leinhäuser _, Andrea Richter, Misu Lee, Ines Höfig, Nataša Anastasov, Falko Fend, Tonino Ercolino, Massimo Mannelli, Anne-Paule Gimenez-Roqueplo, Mercedes Robledo, Ronald de Krijger, Felix Beuschlein, Michael J. Atkinson and Natalia S. Pellegata

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:39111-39126. https://doi.org/10.18632/oncotarget.4912

Metrics: PDF 888 views  |   HTML 1469 views  |   ?  


Abstract

Ines Leinhäuser1,2, Andrea Richter1, Misu Lee1, Ines Höfig2, Nataša Anastasov2, Falko Fend3, Tonino Ercolino4, Massimo Mannelli5, Anne-Paule Gimenez-Roqueplo6,7,8, Mercedes Robledo9, Ronald de Krijger10, Felix Beuschlein11, Michael J. Atkinson2, Natalia S. Pellegata1

1Institute of Pathology, Helmholtz Zentrum München, Neuherberg, Germany

2Institute of Radiation Biology, Helmholtz Zentrum München, Neuherberg, Germany

3Institute of Pathology and Neuropathology Comprehensive Cancer Center Tübingen and University of Tübingen, Tübingen, Germany

4Azienda Ospedaliero-Universitaria di Careggi, Endocrine Unit, Florence, Italy

5Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

6INSERM, UMR U970, Paris Cardiovascular Research Center-PARCC, Paris, France

7Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France

8Assistance Publique Hôpitaux de Paris, Hôpital européen Georges Pompidou, Department of Genetics, Paris, France

9Hereditary Endocrine Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

10Department of Pathology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

11Endocrine Research Unit, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, München, Germany

Correspondence to:

Natalia S. Pellegata, e-mail: natalia.pellegata@helmholtz-muenchen.de

Keywords: pheochromocytoma, bone morphogenic protein 7, PI3K pathway, integrin beta 1, MENX rats

Received: May 22, 2015     Accepted: August 07, 2015     Published: August 18, 2015

ABSTRACT

BMP7 is a growth factor playing pro- or anti-oncogenic roles in cancer in a cell type-dependent manner. We previously reported that the BMP7 gene is overexpressed in pheochromocytomas (PCCs) developing in MENX-affected rats and human patients. Here, analyzing a large cohort of PCC patients, we found that 72% of cases showed elevated levels of the BMP7 protein. To elucidate the role of BMP7 in PCC, we modulated its levels in PCC cell lines (overexpression in PC12, knockdown in MPC and MTT cells) and conducted functional assays. Active BMP signaling promoted cell proliferation, migration, and invasion, and sustained survival of MENX rat primary PCC cells. In PCC, BMP7 signals through the PI3K/AKT/mTOR pathway and causes integrin β1 up-regulation. Silencing integrin β1 in PC12 cells suppressed BMP7-mediated oncogenic features. Treatment of MTT cells with DMH1, a novel BMP antagonist, suppressed proliferation and migration. To verify the clinical applicability of our findings, we evaluated a dual PI3K/mTOR inhibitor (NVP-BEZ235) in MENX-affected rats in vivo. PCCs treated with NVP-BEZ235 had decreased proliferation and integrin β1 levels, and higher apoptosis. Altogether, BMP7 activates pro-oncogenic pathways in PCC. Downstream effectors of BMP7-mediated signaling may represent novel targets for treating progressive/inoperable PCC, still orphan of effective therapy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4912